COVID-19 Vaccine Manufacturing Capacity

KEI has created a public listserve to discuss vaccine manufacturing scale up. (link) February 19, 2021: Roundtable on Pathways to Scale Up Manufacturing Capacity for COVID-19 Vaccines – 19. KEI has gathered data regarding vaccine manufacturing capacity in countries worldwide,… Continue Reading

Exclusive License to NIH Invention Used in Lilly Antibody Treatment Contains Termination Clause and Government-Use Rights

KEI has reviewed an exclusive license between the National Institute of Allergy and Infectious Diseases (NIAID) and AbCellera Biologics (“AbCellera”) concerning a technology invented by NIAID that apparently is being used for the Eli Lilly (“Lilly”) antibody treatment for COVID-19… Continue Reading

Novavax and Inovio COVID-19 Vaccine Contracts Limit Prices Companies Can Charge for Their Products

One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading

President Ursula von der Leyen on COVID-19 (Davos Agenda Week): “And now, the companies must deliver. They must honour their obligations.”

On Tuesday, 26 January 2021, Dr. Ursula von der Leyen, President of the European Commission delivered a special address at “Davos Agenda Week” devoting much of her speech to the European Union’s response to the COVID-19 pandemic. While President von… Continue Reading

EB 148: KEI’s statement on WHO’s Global Observatory on Health R&D

On Friday, 22 January 2021, Knowledge Ecology International delivered the following remarks on WHO”s Global Observatory on Health R&D at the 148th session of WHO’s Executive Board. At meetings of WHO governing bodies, non-State actors are limited to one minute… Continue Reading

WHO EB 148: KEI’s statement on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies

At the meeting of the World Health Organization’s 148th Executive Board, Knowledge Ecology International delivered the following remarks on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies on Friday, 22 January… Continue Reading

Letter from the People’s Vaccine Alliance and Health Action International to Dr. Tedros on C-TAP

On 21 January 2021 the People’s Vaccine Alliance and Health Action International (HAI) sent an open letter to Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), expressing concern about the lack of political support and reported progress… Continue Reading